On the other hand, targeted deletion of Ramp1 reduced normal hematopoiesis under certain stress conditions [39], indicating that the effects of CGRP-CALCRL inhibition on the residual normal hematopoiesis in an AML setting requires thorough investigation. The gene discussed is RAMP1; the disease is acute myeloid leukemia.